Quibim

Quibim is company designing and creating pioneering tools that unlock imaging data to maximize drug programmes and improve patient outcomes. The company uses imaging modalities like MRI, CT, and PET to help detect pathologies and predict outcomes in oncology/immunotherapy, rheumatology, and neurology using an AI-first approach. The main goal is to transform imaging into actionable predictions. Real-world evidence (RWE) and biopharma partners can benefit from Quibim’s expertise in big imaging infrastructures to advance the development of AI models and gain new insights from images. Quibim creates cutting-edge quantitative imaging biomarkers to track the effectiveness of treatments and find new drugs by thoroughly analyzing disease mechanisms. The goal of Quibim is to transform imaging into a catalyst for precision health by leveraging the strength and potential of quantified imaging data and AI. The objectives of Quibim are as follows: (1) Partnering life sciences and RWE companies to develop novel evidence generation from big repositories of real-world imaging data; (2) Leading the evidence generation; and (3) Combining the solutions identified in (1) and the insights extracted in (2) to design and create best-in-class medical devices for the market. Top-tier pharmaceutical companies and Quibim collaborate to advance drug programs through imaging and address healthcare issues by creating image-based predictive AI models. With over 10 million images processed to date, the company has conducted over 50 real-world evidence studies and randomized control trials. More than 125 centers constitute the company’s hospital network. There are 80 people on the team, and the management profiles have worked for some of the top multinational companies in the medical device industry (Philips, HP, Elekta). To date, Quibim has received over €20 million in public and private funding and is a participant in 19 EU projects that have received €30 million in funding.

Role of institution in the project

For EUCAIM, Quibim will adapt its platform and provide the marketplace to meet the requirements related to the analysis, annotation and exploitation of data and third-party data transfer services through QP-Discovery®. Quibim will lead the EUCAIM Data Preprocessing tools and services contributing to the development of imaging quality control and curation.

In addition, Quibim will be in charge of the image and feature harmonization pipelines to guarantee the minimization of batch effects on the datasets used to train models in the EUCAIM infrastructure, providing tools for the harmonization of feature-based datasets.